Lynch, K., Chapman, R., Keshav, S., Montano-Loza, A., Mason, A., Kremer, A., . . . Levy, C. (2019). Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases. Elsevier.
Chicago Style (17th ed.) CitationLynch, K., et al. Effects of Vedolizumab in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Elsevier, 2019.
ציטוט MLALynch, K., et al. Effects of Vedolizumab in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Elsevier, 2019.
אזהרה: ציטוטים אלה לעיתים לא מדויקים ב 100%.